Bevacizumab and Rucaparib in Recurrent Carcinoma of the Cervix or Endometrium

Patients who consent to participate in this study will receive treatment with rucaparib and
bevacizumab until unacceptable toxicity or tumor progression. Subjects will take one
rucaparib pill will be taken twice daily, and bevacizumab will be adimistered via IV onDay 1
of each 21 day cycle. Subjects will receive tests and procedures that are part of regular
cancer care as well as those required for the purposes of this study. If there is no cancer
found in scans after 6 cycles of treatment, patients may continue with study treatment for 1
year. Follow up visits will occur every 3 months for the first 2 years after treatment is
completed and every 6 months for 3 additional years.

Inclusion Criteria:

- Patients with histologically-documented carcinoma of the cervix or endometrium.

- Patients with measurable and/or evaluable lesions as defined by RECIST 1.1.

- Patients who have progressed tumor after first line treatment for Stage 4B, recurrent
or persistent squamous cell or adenocarcinoma of the cervix, or adenocarcinoma of the
endometrium.

- ECOG performance status of 0, 1, or 2.

- Patients must agree to have tumor biopsy for correlative studies.

- Patients must have acceptable organ and marrow function.

- Patients must have a life expectancy of at least 3 months.

- Patients should have no major existing co-morbidities or medical conditions that will
preclude therapy in the view of the principal investigator.

- Prior bevacizumab is allowed if off drug ≥ 28 days prior to study enrollment.

- Female patients of reproductive potential and their male partners must agree to
practice total abstinence or use a highly effective method of contraception prior to
study entry, during treatment and for 6 months following the last dose of rucaparib.

- Negative serum pregnancy test result less than 3 days prior to administration of the
first dose of rucaparib.

Exclusion Criteria:

- Patients who have active second malignancy, i.e., patient known to have potentially
fatal cancer present for which she may be (but not necessarily) currently receiving
treatment.

- Prior treatment with any PARP inhibitor.

- Untreated or symptomatic central nervous system (CNS) metastases.

- Patients with asymptomatic CNS metastases are eligible provided they have been
clinically stable for at least 4 weeks.

- Patients who have received treatment with chemotherapy within 4 weeks (6 weeks for
nitrosoureas or mitomycin C); or radiation, biologic/targeted agents, experimental
drugs within 3 weeks prior to first dose of rucaparib; and/or ongoing adverse effects
from such treatment > NCI CTCAE Grade 1 (Grade 2 non-hematologic toxicity to most
recent treatment may be permitted with prior advanced approval from Sponsor).

- Hospitalization for bowel obstruction within 3 months prior to enrollment.

- Patients must have no history of gross hemoptysis (defined as bright red blood of a ½
teaspoon or more) or coagulopathy.

- Patients with history of major tumor-related bleeding that is not controlled despite
locoregional treatment or at high risk of recurrent tumor-related bleeding will be
excluded.

- Patients should not have a history of thrombosis (e.g. pulmonary embolism or deep
venous thrombosis) and should not be on therapeutic anticoagulation (prophylactic use
of warfarin 1 mg per day is allowed) and INR should be less than 1.5 at registration.

- Patients with history of hypertension must be well-controlled (≤150/100) on a stable
regimen of anti-hypertensive therapy.

- Patients with tumors that invaded major vessels (e.g. the carotid) as shown
unequivocally by imaging studies will be excluded due to the possibility of increased
risk for tumor bleeding with bevacizumab therapy.

- Patients should not have a major surgical procedure, open biopsy, or significant
traumatic injury within 28 days prior to study enrollment, or anticipation of need for
major surgical procedure during the course of the study.

- No history of abdominal fistula, gastrointestinal perforation, or intra-abdominal
abscess within 28 days prior to registration. No serious non-healing wound, ulcer, or
bone fracture.

- Patients should not have unstable angina or myocardial infarction within the previous
6 months; no uncontrolled hypertension; no symptomatic congestive heart failure; no
serious cardiac arrhythmia requiring medication; no clinically significant peripheral
vascular disease; no history of any CNS cerebrovascular ischemia or stroke within the
last 6 months; no active serious infection.

- Patients should not have other coexisting medical condition that would preclude full
compliance with the study.

- Patients may not be receiving any other investigational agents.

- Patients should not have a history of prior severe infusion reaction to a monoclonal
antibody. Patients with known hypersensitivity of Chinese hamster ovary cell products
or other recombinant human antibodies.

- Pregnant women are excluded from this study because rucaparib and bevacizumab have the
potential for teratogenic or abortifacient effects.

- Patients who are breast feeding should discontinue before going on study.

- HIV-positive patients receiving combination anti-retroviral therapy are excluded from
the study because of possible drug interactions with rucaparib and bevacizumab.